• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Gain; Producer Prices Fall In October

    11/15/23 9:57:07 AM ET
    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $CMMB alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones gaining around 90 points on Wednesday.

    Following the market opening Wednesday, the Dow traded up 0.27% to 34,922.07 while the NASDAQ rose 0.36% to 14,144.63. The S&P 500 also rose, gaining, 0.27% to 4,507.75.

    Check This Out: Top 4 Energy Stocks That Are Preparing To Pump This Month

     

    Leading and Lagging Sectors

     

    Consumer staples shares surged by 0.7% on Wednesday.

    In trading on Wednesday, energy shares fell by 0.1%.

     

    Top Headline

     

    Producer prices in the U.S. declined 0.5% month-over-month in October, the most since April 2020 and compared to market estimates of a 0.1% rise.

     

    Equities Trading UP

     

    Chemomab Therapeutics Ltd. (NASDAQ:CMMB) shares shot up 61% to $0.9809 after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease.

    Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) got a boost, shooting 55% to $0.8349 after the company reported mixed third-quarter financial results and issued guidance.

    Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares were also up, gaining 56% to $2.0750 after the company reported third-quarter results.

     

    Equities Trading DOWN

     

    Jaguar Global Growth Corporation I (NASDAQ:JGGC) shares dropped 36% to $4.52.

    Shares of Ispire Technology Inc. (NASDAQ:ISPR) were down 25% to $12.30 after jumping over 50% on Tuesday. The company reported a narrower loss for its first quarter.

    Global-e Online Ltd. (NASDAQ:GLBE) was down, falling 24% to $29.91 as the company reported third-quarter FY23 sales growth of 27% year-over-year, to $133.605 million, missing the consensus of $140.97 million.

    Also Check This Out: Bitcoin Falls Following PPI Data; Kaspa Emerges As Top Gainer

     

    Commodities

     

    In commodity news, oil traded down 1.2% to $77.33 while gold traded down 0.1% at $1,965.60.

    Silver traded up 1.1% to $23.39 on Wednesday while copper rose 0.6% to $3.7050.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 gained 0.5%, London’s FTSE 100 rose 0.8% while Spain’s IBEX 35 Index rose 0.3% The German DAX rose 0.8% French CAC 40 rose 0.4%, while Italy’s FTSE MIB Index climbed 0.5%.

    Industrial production in the Eurozone fell by 1.1% month-over-month in September versus a 0.6% increase in the prior period. The Eurozone recorded a trade surplus of EUR 10 billion in September versus a EUR 29.8 billion gap in the year-ago month.

    The annual inflation rate in Italy fell to 1.7% in October from 5.3% a month ago, while French consumer price inflation was confirmed at 4% year-over-year for the month. UK’s producer prices declined 0.6% year-over-year in October, while inflation rate in the UK fell to 4.6% in October. German wholesale prices declined by 4.2% year-over-year in October.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Wednesday, with Japan’s Nikkei 225 rising 2.52%, Hong Kong’s Hang Seng Index jumping 3.92% and China’s Shanghai Composite Index gaining 0.55%. India’s S&P BSE Sensex, meanwhile, surged 1.14%.

    India’s trade deficit increased to a record high of $31.5 billion in October versus a $26.3 billion gap in the year-ago period. Japan’s industrial production growth was revised higher to 0.5% month-over-month in September versus a preliminary reading of 0.2%, while Japanese economy shrank 2.1% on an annualized basis in the third quarter.

    China's retail sales jumped by 7.6% year-over-year in October, while industrial production rose by 4.6% year-over-year in October.

     

    Economics

     

    Producer prices in the U.S. declined 0.5% month-over-month in October, the most since April 2020 and compared to market estimates of a 0.1% rise.

    The NY Empire State Manufacturing Index climbed 14 points to a reading of 9.1 in November, recording the highest reading since April and versus market estimates of -2.8.

    Now Read This: Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'

    Get the next $CMMB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMMB
    $GLBE
    $HRTX
    $ISPR

    CompanyDatePrice TargetRatingAnalyst
    Global-E Online Ltd.
    $GLBE
    12/11/2025Hold → Sell
    Truist
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    Taysha Gene Therapies Inc.
    $TSHA
    7/11/2025$8.00Buy
    BofA Securities
    Heron Therapeutics Inc.
    $HRTX
    6/9/2025$6.00Buy
    H.C. Wainwright
    Global-E Online Ltd.
    $GLBE
    6/2/2025$31.00Sell
    Truist
    Global-E Online Ltd.
    $GLBE
    3/26/2025$55.00 → $46.00Equal-Weight → Overweight
    Morgan Stanley
    Global-E Online Ltd.
    $GLBE
    10/18/2024$40.00Overweight → Equal-Weight
    Morgan Stanley
    Taysha Gene Therapies Inc.
    $TSHA
    6/27/2024$5.00Outperform
    BMO Capital Markets
    More analyst ratings

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units (RSUs) representing 349,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering empl

    2/6/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

    Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

    2/4/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Rubric Capital Management Lp bought $3,580,838 worth of shares (2,387,225 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 6:00:17 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Morgan Adam bought $2,649,819 worth of shares (1,766,546 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 5:02:36 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Manning Paul B bought $2,062,500 worth of shares (750,000 units at $2.75) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    6/3/25 9:38:27 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.

    SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    2/5/26 1:40:12 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Taysha Gene Therapies Inc.

    144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    2/4/26 6:44:01 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Global-E Online downgraded by Truist

    Truist downgraded Global-E Online from Hold to Sell

    12/11/25 8:52:49 AM ET
    $GLBE
    Computer Software: Prepackaged Software
    Technology

    Raymond James initiated coverage on Taysha Gene Therapies with a new price target

    Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00

    10/21/25 7:22:35 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Taysha Gene Therapies with a new price target

    BofA Securities initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $8.00

    7/11/25 8:16:08 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Alam Kamran sold $7,481 worth of shares (1,655 units at $4.52), decreasing direct ownership by 0.11% to 1,442,131 units (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    2/6/26 4:30:29 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Cusack Thomas was granted 53,960 shares (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:07 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Financial Officer Duarte Ira

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:10 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Global-e to Announce Financial Results for the Fourth Quarter and Full Year 2025 on February 18, 2026

    PETAH-TIKVA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Global-e Online Ltd. (NASDAQ:GLBE), the platform powering global direct-to-consumer e-commerce, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, before market open on Wednesday, February 18, 2026. Global-e management will host a conference call to review its financial results and outlook. Date:Wednesday, February 18, 2026Time:8:00 AM ETUnited States/Canada Toll Free:+1-800-717-1738International Toll:+1-646-307-1865   Please join the call 5-10 minutes prior to the scheduled start time, to avoid a delay in connecting. A live webcast will be available in the Investor Relations

    2/3/26 8:38:41 AM ET
    $GLBE
    Computer Software: Prepackaged Software
    Technology

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

    SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/29/24 3:04:59 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

    SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/21/24 10:59:28 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMMB
    $GLBE
    $HRTX
    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

    CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance. 

    10/29/25 5:58:14 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care